Home Biotechnology AbbVie Inc.
A

AbbVie Inc.

Profile managed by Bizz Id
United States 500+ employees 2013

Description

Biopharmaceutical company founded in 2013 and headquartered in North Chicago, Illinois, USA. It develops and markets medicines in immunology, oncology, neuroscience, eye care and medical aesthetics, with products in more than 175 countries and about 57,000 employees.

Products

38 products
ABBV-142 (anti-LPAR1)

LPAR1 antagonist antibody. Idiopathic pulmonary fibrosis Phase 2.

Under development

Finished product (FDF)

Verified on 2026-10-21

ABBV-1451 (anti-IL-1a/1b)

Next-generation anti-IL-1a/b antibody. Hidradenitis suppurativa Phase 1.

Under development

Finished product (FDF)

Verified on 2026-10-21

ABBV-1480 (anti-PD-1/VEGF)

RC148. PD-1/VEGF bispecific antibody. Solid tumors Phase 1.

Under development

Finished product (FDF)

Verified on 2026-10-21

ABBV-1758 (anti-3pE-Aβ)

Pyroglutamate amyloid beta (3pE-Aβ) antibody with anti-TfR delivery module. Alzheimer's disease Phase 1.

Under development

Finished product (FDF)

Verified on 2026-10-21

ABBV-2001 (anti-CD38/BCMA/CD3)

ISB 2001. Trispecific T-cell engager targeting CD38, BCMA and CD3. R/R multiple myeloma Phase 1.

Under development

Finished product (FDF)

Verified on 2026-10-21

ABBV-2002 (anti-PAR-2)

Monoclonal antibody targeting PAR-2. Migraine prevention Phase 2.

Under development

Finished product (FDF)

Verified on 2026-10-21

ABBV-243 (anti-integrin β7)

Integrin β7 antibody (α4β7 and αEβ7). Inflammatory bowel disease Phase 1.

Under development

Finished product (FDF)

Verified on 2026-10-21

ABBV-273 (anti-IL-13 + TSLP)

Long-acting combination of zumilokibart (IL-13) and TSLP targeting. Asthma Phase 1.

Under development

Finished product (FDF)

Verified on 2026-10-21

ABBV-313 (anti-IL-13/IL-31R)

Bispecific anti-IL-13/IL-31R antibody. Atopic dermatitis Phase 1.

Under development

Finished product (FDF)

Verified on 2026-10-21

ABBV-319 (anti-CD19 ADC)

Steroid-based ADC targeting CD19. Systemic lupus erythematosus and Sjogren's disease Phase 1.

Under development

Finished product (FDF)

Verified on 2026-10-21

ABBV-438 (anti-CD38 ADC)

ADC targeting CD38. Multiple myeloma Phase 1.

Under development

Finished product (FDF)

Verified on 2026-10-21

ABBV-466 (risankizumab + anti-a4b7)

Risankizumab + ABBV-382 (anti-a4b7 mAb) combination. Inflammatory bowel disease Phase 2.

Under development

Finished product (FDF)

Verified on 2026-10-21

ABBV-519 (anti-CD19)

Anti-CD19 antibody. Systemic lupus erythematosus and rheumatoid arthritis Phase 1.

Under development

Finished product (FDF)

Verified on 2026-10-21

ABBV-547 (anti-IL-23)

Next-generation anti-IL-23 antibody. Psoriasis Phase 1.

Under development

Finished product (FDF)

Verified on 2026-10-21

ABBV-6628 (anti-C5 fragment)

Monoclonal antibody fragment targeting C5. Geographic atrophy Phase 1.

Under development

Finished product (FDF)

Verified on 2026-10-21

ABBV-706 (anti-SEZ6 ADC)

SEZ6-targeted ADC with a Top1i payload. R/R small cell lung cancer Phase 3; first line Phase 2; neuroendocrine neoplasms Phase 1.

Under development

Finished product (FDF)

Verified on 2026-10-21

ABBV-7066 (risankizumab + anti-TL1A)

Risankizumab + ABBV-701 (anti-TL1A mAb) combination. Inflammatory bowel disease Phase 2.

Under development

Finished product (FDF)

Verified on 2026-10-21

ABBV-8736 (anti-TREM1)

Anti-TREM1 antibody. Crohn's disease Phase 2.

Under development

Finished product (FDF)

Verified on 2026-10-21

ABBV-901 (anti-FRα ADC)

Folate receptor alpha ADC. Ovarian cancer Phase 1.

Under development

Finished product (FDF)

Verified on 2026-10-21

ABBV-969 (anti-PSMA/STEAP1 ADC)

ADC targeting PSMA and STEAP1. mCRPC Phase 1.

Under development

Finished product (FDF)

Verified on 2026-10-21

Adalimumab

Brand: Humira. Marketed in the US (abbvie.com product list).

Comercializado (agencia no indicada)

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Adalimumab: see suppliers →

Azirkitig

ABBV-514. Anti-CCR8 antibody. Solid tumors Phase 1.

Under development

Finished product (FDF)

Verified on 2026-10-21

Azirkitig: see suppliers →

Epcoritamab

Brand: Epkinly (US), Tepkinly (EU) (epcoritamab-bysp). CD3xCD20 bispecific antibody (DuoBody, Genmab). Approved in R/R DLBCL (US, EU) and R/R follicular lymphoma; R/R CLL Phase 2, 1L FL and 1L DLBCL Phase 3.

Aprobado (EE. UU.); Aprobado (UE)

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Epcoritamab: see suppliers →

Etentamig

ABBV-383. BCMA x CD3 T-cell engaging bispecific antibody. R/R multiple myeloma Phase 3; AL amyloidosis Phase 2.

Under development

Finished product (FDF)

Verified on 2026-10-21

Etentamig: see suppliers →

GemibotulinumtoxinA

GemibotA. Next-generation toxin (target SNAP-25). Essential tremor Phase 2; ventral hernia repair Phase 2.

Under development

Finished product (FDF)

Verified on 2026-10-21

GemibotulinumtoxinA: see suppliers →

IMGN-151 (anti-FRα ADC)

Biparatopic folate receptor alpha ADC with DM21 payload. Gynecologic cancers Phase 2.

Under development

Finished product (FDF)

Verified on 2026-10-21

Lutikizumab

ABT-981. IL-1a/1b antagonist. Hidradenitis suppurativa Phase 3.

Under development

Finished product (FDF)

Verified on 2026-10-21

Lutikizumab: see suppliers →

Lutikizumab + Ravagalimab

ABBV-9832. IL-1a/1b antagonist + CD40 antagonist combination. Rheumatoid arthritis Phase 2.

Under development

Finished product (FDF)

Verified on 2026-10-21

Lutikizumab: see suppliers → · Ravagalimab: see suppliers →

Mirvetuximab soravtansine

Brand: Elahere (mirvetuximab soravtansine-gynx). Folate receptor alpha-targeting ADC with DM4 payload. Approved in platinum-resistant ovarian cancer; platinum-sensitive in Phase 3.

Aprobado (agencia no indicada)

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Mirvetuximab soravtansine: see suppliers →

OnabotulinumtoxinA (BOTOX Cosmetic)

Brand: BOTOX Cosmetic. Marketed in the US.

Comercializado (agencia no indicada)

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

OnabotulinumtoxinA: see suppliers →

OnabotulinumtoxinA (BOTOX)

Brand: BOTOX. Neurotoxin (target: SNARE proteins). Approved in the US (platysma prominence) and China (masseter prominence, forehead lines); masseter prominence in Phase 3 elsewhere.

Aprobado (EE. UU.); Aprobado (China)

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

OnabotulinumtoxinA: see suppliers →

Pivekimab sunirine

Brand: Decnupaz (pivekimab sunirine-pvzy). CD123-targeting ADC with an indolinobenzodiazepine payload. Approved in the US for BPDCN; acute myeloid leukemia in Phase 2.

Aprobado (EE. UU.)

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Pivekimab sunirine: see suppliers →

Risankizumab

Brand: Skyrizi (risankizumab-rzaa). Anti-IL-23 antibody. Marketed in the US.

Comercializado (agencia no indicada)

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Risankizumab: see suppliers →

Risankizumab + Lutikizumab

ABBV-166. Anti-IL-23 + IL-1a/1b combination. Psoriatic arthritis Phase 2.

Under development

Finished product (FDF)

Verified on 2026-10-21

Risankizumab: see suppliers → · Lutikizumab: see suppliers →

Telisotuzumab adizutecan

Temab-A (ABBV-400). c-Met-targeting ADC with a topoisomerase 1 inhibitor payload. Colorectal cancer Phase 3; other solid tumors Phase 2.

Under development

Finished product (FDF)

Verified on 2026-10-21

Telisotuzumab adizutecan: see suppliers →

Telisotuzumab vedotin

Brand: Emrelis (telisotuzumab vedotin-tllv). Marketed in the US.

Comercializado (agencia no indicada)

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Telisotuzumab vedotin: see suppliers →

TrenibotulinumtoxinE

Pipeline name: Boey. Toxin for glabellar lines. Approved in the EU.

Aprobado (UE)

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

TrenibotulinumtoxinE: see suppliers →

Zumilokibart

Half-life extended anti-IL-13 monoclonal antibody. Atopic dermatitis Phase 2.

Under development

Finished product (FDF)

Verified on 2026-10-21

Zumilokibart: see suppliers →

Contact company

Register for free to see this company’s contact details and get in touch.

Register - Free